Navigation Links
Arbitration Panel Issues Ruling in Distribution Dispute
Date:7/25/2008

WALTHAM, Mass., July 25 /PRNewswire-FirstCall/ -- Inverness Medical Innovations, Inc. (Amex: IMA), a leading provider of rapid diagnostic products and health management services, announced that it received today a decision from an arbitration tribunal. That decision, directed at Inverness' Binax subsidiary, awards Binax's distributor in Spain and Portugal approximately $13.8 million, including interest and arbitration related expenses. While Inverness is reviewing the decision and will evaluate its next steps, the terms of the distribution agreement provide limited remedies to Inverness related to the tribunal's decision.

Inverness will record an after tax charge of approximately $8.6 million or $0.10 per diluted share related to the decision in its earnings for the second quarter of 2008, which are scheduled to be released on July 29, 2008.

About Inverness

By developing new capabilities in near-patient diagnosis, monitoring and health management, Inverness Medical Innovations enables individuals to take charge of improving their health and quality of life. A global leader in rapid point-of-care diagnostics, Inverness' products, as well as its new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Inverness is headquartered in Waltham, Massachusetts. For more information about Inverness Medical Innovations, please visit http://www.invernessmedical.com.

Statement under the Private Securities Litigation Reform Act

This press release contains forward-looking statements within the meaning of the federal securities laws. Actual results may differ materially due to numerous factors, including without limitation, the demand for Inverness' current and future products; the ability of Inverness to efficiently manufacture those products and the risks and uncertainties described in Inverness' periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.


'/>"/>
SOURCE Inverness Medical Innovations, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
2. Expert Consensus Panel Recommendation for Incorporating Lp-PLA2 Testing into Cardiovascular Disease Risk Assessment Guidelines
3. Insmed to Request Hearing Before NASDAQ Panel to Review NASDAQ Staff Determination
4. Paul Capital Healthcare Leads Panel on Strategic Financing
5. WIPO Panel Rules Boston Scientific Liberte(R) and TAXUS(R) Liberte(R) Stents Do Not Infringe Medinol Patents
6. DuPont Strengthens Commitment to Responsible Science with New Biotech Advisory Panel Members
7. BioMS Medical to Participate in Speciality Panel Session at BioFinance 2008
8. Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease
9. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
10. Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
11. Advanced Life Sciences to Host Conference Call to Discuss Announcement Made Yesterday by FDA to Conduct Advisory Panel on CAP Drug Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... PA (PRWEB) , ... May 22, 2017 , ... ... announced today that it is exhibiting in booth B2 at the Association for ... Pittsburgh, May 22-25. , In addition to demonstrating its Cancer Diagnostic Cockpit ...
(Date:5/19/2017)... ... May 19, 2017 , ... ... Program. Academic researchers with technologies ripe for commercialization, and who are affiliated ... Delaware, are encouraged to submit proposals. QED, now in its tenth round, is ...
(Date:5/18/2017)... ROCHELLE, VIRGINIA (PRWEB) , ... May 17, 2017 , ... ... senior business executive and former CEO of Eurofins Advantar Laboratories and President of Pharmaceutical ... In addition to his position at Eurofins and Cardinal Health, he was former Chief ...
(Date:5/18/2017)... ... May 17, 2017 , ... HOLLOWAY AMERICA, a ... food and dairy, munitions, and pharmaceutical/biotech, recently introduced The Revolution Lift™, a new ... The improvement in technology comes on the heels of HOLLOWAY’s release of the ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017 The research team ... for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint ... new realm of speed and accuracy for use in identification, crime ... affordable cost. ... A ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health Services ... Management Systems Society (HIMSS) Analytics for achieving Stage ... Model sm . In addition, CHS previously earned ... hospitals using an electronic medical record (EMR). ... high level of EMR usage in an outpatient ...
(Date:3/23/2017)... Mar. 23, 2017 Research and Markets has ... Analysis & Trends - Industry Forecast to 2025" report to ... ... a CAGR of around 8.8% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
Breaking Biology News(10 mins):